There are currently 813 clinical trials in Jacksonville, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic in Florida, Mayo Clinic - Jacksonville, Mayo Clinic and Mayo Clinic Florida. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
[18F]PI-2620 Phase 3 Histopathological Study
NCT05641688
Recruiting
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/21/2025
Locations: UF College of Medicine - Jacksonville, Jacksonville, Florida
Conditions: Alzheimer Disease
Register for Updates
Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects with an IPAA (PROF)
NCT05938465
Recruiting
The aim of this study is to assess the safety and preliminary efficacy of treatment with EXE-346, a live biotherapeutic, which may reduce bowel movement frequency in patients with an ileal pouch-anal anastomosis (IPAA) and lead to a higher quality of life.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Mayo Clinic - Florida (Inflammatory Bowel Disease Center), Jacksonville, Florida
Conditions: Ileal Pouch
Register for Updates
Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients with Breast Cancer Undergoing Nipple Sparing Mastectomy and Reconstruction
NCT06153836
Recruiting
This phase II trial tests the willingness of patients undergoing nipple sparing mastectomy (NSM) to enroll in a randomized study of NSM with or without neurotization of the nipple areolar complex (NAC). This trial also compares patient reported outcomes, including quality of life and breast and NAC sexual functionality, for patients undergoing NSM with or without neurotization of the NAC. NSM is a standard practice option for patients undergoing preventative mastectomy, but many report dissatisf... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
Register for Updates
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults with Refractory or Unexplained Chronic Cough
NCT06504446
Recruiting
This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/21/2025
Locations: Jacksonville Center for Clinical Research, Jacksonville, Florida
Conditions: Refractory or Unexplained Chronic Cough
Register for Updates
Virtual Reality for Non-cardiac Chest Pain
NCT06262126
Recruiting
The purpose of this study is to determine if virtual reality (VR) will improve symptoms in non-cardiac chest pain (NCCP).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Gastrointestinal Diseases, Chest Pain
Register for Updates
PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm
NCT06445608
Recruiting
This purpose of this trial is to demonstrate 30 day safety and effectiveness outcomes of the KARDION CORY P4 System in subjects who require hemodynamic support during a high-risk PCI procedure.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/21/2025
Locations: Ascension St. Vincent's, Jacksonville, Florida
Conditions: Coronary Artery Disease
Register for Updates
A Study of a Novel Precision Medicine Approach for Obesity
NCT06814938
Recruiting
This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/21/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Obesity
Register for Updates
A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder
NCT06648655
Recruiting
TMP-301 has been shown in preclinical models to reduce consumption of alcohol and other addictive substances. It has been tested in healthy subjects and has been found to be safe and tolerated at doses predicted to be efficacious in alcohol use disorder. This study is being conducted to evaluate the safety, tolerability and efficacy of TMP-301 in patients with alcohol use disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/20/2025
Locations: CNS Healthcare- Jackson, Jacksonville, Florida
Conditions: Alcohol Use Disorder (AUD)
Register for Updates
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 CtHPV-DNA
NCT05541016
Recruiting
This phase II trial examines the use of blood-based biomarkers is to help inform decision making for treatment and radiation therapy for patients with human papillomavirus (HPV) positive oropharyngeal squamous cell cancers. The standard treatments for head and neck cancers are radiation therapy with chemotherapy or surgery potentially followed by radiation therapy with or without chemotherapy. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving chemotherapy alon... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Register for Updates
Evaluating the Association Between Changes in the Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer
NCT05417867
Recruiting
This pilot study seeks to understand how changes in the bacteria composition (microbiome) of the gut may be associated with the occurrence of fatigue and chemotherapy-induced nausea (CIN) in women undergoing chemotherapy for early stage breast cancer. Patients undergoing chemotherapy may experience fatigue or nausea as a result of their treatment. Known risk factors for fatigue and CIN do not explain the differences in fatigue and CIN occurrence between patients, but changes in the functions of... Read More
Gender:
ALL
Ages:
20 years and above
Trial Updated:
02/20/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Chemotherapy-Related Nausea and/or Vomiting, Early Stage Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Register for Updates
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302
Recruiting
The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Lymphoma, Follicular
Register for Updates
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
NCT06627647
Recruiting
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Research Site, Jacksonville, Florida
Conditions: Non-squamous Non-small Cell Lung Cancer
Register for Updates